Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

Cytotherapy - 1 Jul 2018

Murad Joana M, Baumeister Susanne H, Werner Lillian, Daley Heather, Trébéden-Negre Hélène, Reder Jake, Sentman Charles L, Gilham David, Lehmann Frederic, Snykers Sarah, Sentman Marie-Louise, Wade Terri, Schmucker Adam, Fanger Michael W, Dranoff Glenn, Ritz Jerome, Nikiforow Sarah

Abstract excerpt

BACKGROUND AIMS: Adoptive cell therapy employing natural killer group 2D (NKG2D) chimeric antigen receptor (CAR)-modified T cells has demonstrated preclinical efficacy in several model systems, including hematological and solid tumors. We present comprehensive data on manufacturing development and clinical production of autologous NKG2D CAR T cells for treatment of acute myeloid leukemia and multiple myeloma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ligands

Share to NK Cell Lectin-Like Receptor Subfamily K

Share to Receptors, Antigen, T-Cell

Share to Receptors, Chimeric Antigen

Share to T-Lymphocytes

Share to Transplantation, Autologous

Source

Open in PubMed Open full text

Identifiers

PMID: 30180944
DOI: 10.1016/j.jcyt.2018.05.001
PMCID: PMC6127861

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.PMID 30180944Read ↗

Recent Progress in NKG2D CAR-NK Cells for Cancer ImmunotherapySemantic proximity Read ↗

Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cellsSemantic proximity Read ↗

Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blastsSemantic proximity Read ↗

CAR<sup>+</sup> and CAR<sup>-</sup> T cells differentiate into an NK-like subset that is associated with increased inflammatory cytokines following infusionSemantic proximity Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

CAR+ and CAR- T cells differentiate into an NK-like subset that is associated with increased inflammatory cytokines following infusionSemantic proximity Read ↗

Current status and perspective of CAR-T and CAR-NK cell therapy trials in GermanySemantic proximity Read ↗

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read ↗

Solid tumor immunotherapy using NKG2D-based adaptor CAR T cellsSemantic proximity Read ↗

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.Semantic proximity Read ↗

Automated GMP-Compatible Production of Universal CAR Tregs for Organ-Targeted Tolerance InductionSemantic proximity Read ↗

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.